The CHPA Dietary Supplements Committee supports maintaining A-priority level for several goals listed in the 2005 Program Priorities that specifically address dietary supplement issues. We also support efforts to fully implement the Dietary Supplement Health and Education Act of 1994 as currently written.
CHPA and CTFA request a 60-day extension of the comment period on the Draft Guidance for Industry on Gingivitis: Development and Evaluation of Drugs for the Treatment and Prevention.
Comments of Consumer Healthcare Products Association before the Institute of Medicine of the National Academies Committee on identifying and preventing medication errors.
Members of the Consumer Healthcare Products Association appreciate the opportunity to nominate an industry representative to serve on the FDA Food Advisory Committee.
CHPA appreciates the opportunity to provide comments concerning U.S. Government positions in preparation for the 33rd session of the Codex Committee on Food Labelling of the Codex Alimentarius Commission.
In considering the safety of NSAIDs, the use of OTC NSAIDs should be clearly distinguished from long-term prescription NSAID use. OTC medicines have a different overall benefit-to-risk equation and a wider margin of safety than prescription NSAIDs.
CHPA appreciates the opportunity to provide comments on the premarket notification for new dietary ingredient (NDI) notifications for dietary supplements.
CHPA appreciates the opportunity to provide comments to the FDA in response to the draft guidance for industry “Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions”.
Given the millions of units of tooth whitening products used by U.S. consumers and the remarkable safety profile of these products, we believe the U.S. data supports the Colipa recommendation for the marketing of cosmetic tooth whitening products.
